SCHEMBL15516593

SCHEMBL15516593

NNC(=O)COc1cccnc1N1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.56
▸ OGG1 O15527 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ RAB9A P51151 1/20 0.44
▸ KMT2A Q03164 3/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP2C9 P11712 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ L3MBTL1 Q9Y468 4/20 0.43
▸ LMNA P02545 2/20 0.43
▸ MAPK1 P28482 2/20 0.43
▸ USP2 O75604 2/20 0.43
▸ ALOX15 P16050 2/20 0.43
▸ ATM Q13315 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15517728 0.83 L3MBTL1 (0.48) MAPTALDH1A1KDM4EKMT2ACYP1A2
SCHEMBL15517101 0.75 MAPT (0.65) MAPTOGG1ALDH1A1KDM4ERAB9A
SCHEMBL15516810 0.75 MAPT (0.65) MAPTOGG1ALDH1A1KDM4ERAB9A
SCHEMBL6890494 0.73 MAPT (0.49) MAPTALDH1A1KDM4EKMT2ACYP1A2
SCHEMBL28678208 0.72 MAPT (1.00) MAPTOGG1ALDH1A1KDM4ERAB9A
SCHEMBL31026266 0.71 OGG1 (0.65) MAPTOGG1ALDH1A1KDM4ERAB9A
SCHEMBL27815937 0.69 CYP1A2 (0.51) ALDH1A1KDM4ERAB9ACYP1A2CYP2C9
SCHEMBL315250 0.68 MAPT (0.55) MAPTOGG1ALDH1A1KDM4EKMT2A
SCHEMBL883905 0.68 KMT2A (0.58) MAPTALDH1A1KDM4EKMT2ACYP1A2
SCHEMBL38658667 0.68 L3MBTL1 (0.62) MAPTALDH1A1KMT2ACYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2890677-B1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2017-11-15 — — EP disclosed
US-9447083-B2 N-acylhydrazone derivatives for selective T cell inhibitor and anti-lymphoid malignancy drug CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2016-09-20 — — US disclosed
US-20150252030-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2015-09-10 — — US disclosed
EP-2890677-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG Chong Kun Dang Pharmaceutical Corp. (KR) 2015-07-08 — — EP disclosed
WO-2014035149-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2014-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252030-A1 N-ACYLHYDRAZONE DERIVATIVES FOR SELECTIVE T CELL INHIBITOR AND ANTI-LYMPHOID MALIGNANCY DRUG MALT1, MCL1, ACIN1 MAPT 4342/4885OGG1 2965/4885ALDH1A1 769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback